Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.82
- Piotroski Score 2.00
- Grade Hold
- Symbol (CARA)
- Company Cara Therapeutics, Inc.
- Price $0.31
- Changes Percentage (0.98%)
- Change -$0
- Day Low $0.30
- Day High $0.32
- Year High $1.68
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $13.50
- High Stock Price Target $30.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.26
- Trailing P/E Ratio -0.28
- Forward P/E Ratio -0.28
- P/E Growth -0.28
- Net Income $-118,513,000
Income Statement
Quarterly
Annual
Latest News of CARA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Injured Alexander Isak ruled out of Carabao Cup tie, will be assessed before Everton trip
Alexander Isak will miss Newcastle United's Carabao Cup match due to a broken toe. Coach Eddie Howe says the injury is not serious, but Isak's status for the Everton game is uncertain....
By The New York Times | 2 days ago -
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors
RA Capital Management disclosed acquiring 6,955,993 shares of Bicara Therapeutics, a clinical-stage biopharmaceutical company, at $18 per share during its IPO on Sept. 16. This represents a 12....
By MarketWatch | 3 days ago -
Stocks To Watch: Bicara Therapeutics Sees RS Rating Rise To 83
Learn how to trade options effectively by selecting the right strategy for best results. Understand the importance of RS Rating in identifying market leadership and recognizing top-performing stocks. ...
By Investor's Business Daily | 4 days ago
